![]() | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Nial J. Wheate | |
---|---|
![]() Wheate in 2022 | |
Born | 1976 (age 48–49) Werribee, Victoria, Australia |
Nationality | Australian |
Alma mater | University of New South Wales |
Scientific career | |
Fields | Chemistry |
Institutions | University of Sydney University of Strathclyde University of Western Sydney |
Doctoral advisor | J. Grant Collins |
Nial J. Wheate (born 1976) is an Australian pharmaceutical chemist and author who currently works at the University of Sydney in Australia.
After graduating from Copland College in Canberra, Australia, Wheate was commissioned as an officer in the Royal Australian Navy. He attended the Australian Defence Force Academy, [1] where he earned a Bachelor of Science degree, double majoring in chemistry, and graduated in 1997 with First Class Honours. After a brief appointment as a Visiting Military Scholar, he completed a PhD under the supervision of Associate Professor J. Grant Collins within the School of Physical, Environmental and Mathematical Sciences at the University of New South Wales, with a thesis titled "Platinum Anticancer Drugs" in 2001. [2]
Over the next three years, he was posted to the School of Air Navigation (now the School of Air Combat) at RAAF Base East Sale, the Air Coordination and Policy Agency, the Joint Health Support Agency, and the Sea Power Centre – Australia. [3] He left the navy in 2005. He was then appointed a Senior Fellow in the School of Biomedical and Health Sciences at the University of Western Sydney before being appointed as a lecturer in medicinal chemistry at the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde in Glasgow, Scotland. He is currently an Associate Professor in the Faculty of Medicine and Health at the University of Sydney. In 2013, he was appointed Head of Cancer Research within the Faculty of Pharmacy. [4] In March 2019, he was appointed to the board of Canngea Pty Ltd, an Australian medicinal cannabis manufacturer, as Science Director. [5]
Wheate's research interests are in the field of metal-based drugs. His research group's work includes drug design and synthesis, encapsulation of drugs in macrocycles, attachment of drugs to nanoparticles, drug solid-state stability and polymorphism (materials science), drug mechanisms of action, improving drug solubility through the formation of cocrystals, drug metabolism, drug pre-formulation and formulation, and drug-excipient interactions in various dosage forms. His work has included the development of magnetically directed drug delivery for platinum drugs. [6]
Wheate's work has focused on multinuclear platinum-based drugs [7] and the potential applications of cucurbiturils for drug delivery. [8]
In 2013, Wheate was elected a Fellow of the Royal Australian Chemical Institute in recognition of his work in cancer research [9] and is also a senior fellow of the Higher Education Academy. [10]
Wheate was previously an associate editor of the Australian Journal of Chemistry.
Wheate has also published in a variety of other areas, including military justice, [11] naval history, [12] [13] weapons of mass destruction, [14] and he has written a novel titled Whikatak Island. [15]
{{cite web}}
: CS1 maint: multiple names: authors list (link){{cite web}}
: CS1 maint: archived copy as title (link){{cite web}}
: CS1 maint: archived copy as title (link) The chemical, biological, radiological and nuclear threat, Papers in Australian Maritime Affairs, 2006, 19, 71-76.